News for NantHealth, Inc. (NH)

NantHealth names Scott Maratea as new Chief Revenue Officer

Winterville, NC - April 3, 2024 - NantHealth, Inc. , proudly announces the expansion of its product leadership team by appointing three seasoned executives who will spearhead efforts to...

Rising adoption of bio chips for analyzing biomolecules, proteins, and Deoxyribonucleic Acid (DNA) is a major factor driving Biochips market revenue...

Rising demand for data analytics solutions in the healthcare industry and growing emphasis on patient safety and quality of care are key factors driving...

/PRNewswire/ -- The "Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides...

On September 7, 2023, Nant Capital, LLC announced that it has been and may continue to be in contact with members of NantHealth, Inc?s management, the Company?s board of directors, other significant...

Spok Holdings recently saw a decline in its stock price without a reasonable justification, in my view. Find out if now is a good time to buy SPOK stock.

SkyQuest projects that the medical image management market will attain a value of USD 7.22 billion by 2030, with a CAGR of 7.6% over the forecast period...

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.69%

The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.55 A.M. ET)..

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.85%

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.

Read NantHealth (NASDAQ:NH) & CooTek (Cayman) (NYSE:CTK) Head-To-Head Review at ETF Daily News

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly traded company.

Read Analysts’ New Coverage for May 29th (AACG, AAME, ABEO, ACOR, ACRX, ACU, AEMD, AEY, AEZS, AGFS) at ETF Daily News

Read Investment Analysts’ New Coverage for May 21st (AACG, AAME, ABEO, ACOR, ACRX, ACU, AEMD, AEY, AEZS, AGFS) at ETF Daily News

NantHealth, Inc. (NASDAQ:NH) Q4 2020 Results Earnings Conference Call February 25, 2021, 4:30 PM ET Company Participants Robert Jaffe - Investor Relations Officer Ron Louks - Chief...

Papa John’s International delivered lower-than-expected earnings in the fourth quarter. Meanwhile, shares of Papa John’s fell 7.4% in pre-market trading as the company posted earnings per share (EPS) of $0.40 during the fourth quarter, which were behind analysts’ expectations of $0.46. That said, revenue increased 12.5% year-on-year to $469.8 million, topping analysts’ estimates of $465.7 million. The increase in 4Q revenues was primarily attributable to higher comparable sales for North America restaurants, which saw 10.2% growth in company owned restaurants and 14.5% growth in franchised restaurants. Papa John’s (PZZA) international sales also increased on the back of higher commissary revenues and royalties resulting from comparable sales growth of 21.4%. For fiscal 2020, the company generated sales of $1.81 billion, up 12% from 2019. Diluted earnings per share came in at $1.40, versus $0.03 in the comparable year-ago period. Papa John’s President and CEO Rob Lynch said, “4Q was the third consecutive quarter of double-digit comparable sales growth and the sixth straight quarter of positive comparable sales in North America. We ended the year with the launch of Epic Stuffed Crust, the biggest product innovation in the company’s history, and our future is extremely bright.” In light of ongoing uncertainity about the future impact from the COVID-19 pandemic, Papa John’s did not provide any guidance. (See Papa John’s stock analysis on TipRanks) On Feb. 23, Deutsche Bank analyst Brian Mullan raised the price target to $110 (7.2% upside potential) from $91 and reiterated a Buy rating. Mullan believes the outlook for Papa John’s shares from here is favorable with a 12-month view. Turning to Wall Street, Papa John’s has a Strong Buy consensus rating based on 8 Buys and 1 Hold. The average analyst price target of $111.13 implies about 8.3% upside potential from current levels. Papa John’s stock has seen a runup of about 50% over the past year. Related News: Fisker Inks MOU With Foxconn To Develop EV; Shares Pop 22% Pre-Market Upwork Posts Better-Than-Expected 4Q Results; Shares Pop 18.7% After-Hours Nvidia Posts Better-Than-Expected 4Q Earnings; Street Remains Bullish More recent articles from Smarter Analyst: Jumia 4Q Revenues Miss Estimates, Losses Narrow To €40M Radian Group’s 4Q Earnings Beat Estimates; Street Sees 29% Upside Moderna Plans To Increase Supply Capacity For COVID-19 Vaccine; Shares Spike 5% Bilibili’s 4Q Sales Beat Analysts’ Estimates; Shares Rise 3.8%